|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,497,393: Scope, Claims, and Patent Landscape
Executive Summary
Patent 8,497,393, entitled "Methods of treating cancer", was granted by the United States Patent and Trademark Office (USPTO) on July 23, 2013. It pertains to novel methods involving the administration of specific pharmaceutical combinations for cancer therapy, with a primary focus on targeted treatments using kinase inhibitors. This patent’s scope centers on combination therapies employing epidermal growth factor receptor (EGFR) inhibitors and other agents, providing a method of improving treatment efficacy or reducing side effects.
The patent encompasses claims that cover specific combinations, dosages, and methods of treatment involving the drug afatinib (BIBW 2992) and other agents, particularly in treating non-small cell lung carcinoma (NSCLC) and other cancers expressing EGFR mutations.
The patent landscape surrounding 8,497,393 reveals active competition among major pharmaceutical companies developing targeted cancer therapies, notably in EGFR inhibition. A comprehensive review of its claims, scope, and landscape shows that it plays a significant role in the patent rights pertaining to combination therapies involving kinase inhibitors, particularly in lung cancer.
Summary of Patent 8,497,393
| Attribute |
Details |
| Patent Number |
US 8,497,393 B2 |
| Title |
Methods of treating cancer |
| Filing Date |
May 14, 2010 |
| Issue Date |
July 23, 2013 |
| Assignee |
Boehringer Ingelheim International GmbH |
| Inventors |
Dominik M. F. Schrenk, et al. |
| Patent Family |
Filed internationally under PCT, with national phase entries in multiple jurisdictions |
Scope of the Patent
Core Focus:
The patent claims a method of treating a subject having a cancer characterized by abnormal EGFR activity, involving administering a combination of:
- An EGFR tyrosine kinase inhibitor (e.g., afatinib),
- An additional anti-cancer agent (e.g., chemotherapeutic agents, other kinase inhibitors),
- In specific dosages and sequences.
Key Aspects of Scope:
- Treatments primarily targeting NSCLC harboring EGFR mutations.
- Use of afatinib in combination with other drugs (e.g., chemotherapy or targeted agents).
- Methods involving specific dosage schedules (e.g., daily administration over a defined period).
- Application in patients with specific biomarker profiles, such as activating EGFR mutations.
Limitations & Exclusions:
- The claims exclude monotherapy use of afatinib, focusing explicitly on combination therapy.
- The scope does not extend to all forms of cancer but concentrates on EGFR mutation-positive tumors.
- Specific dosage ranges, e.g., afatinib at doses between 20–50 mg/day.
Claims Analysis
Number of Claims: 22 (including independent and dependent claims)
Independent Claims
- Claim 1: A method involving administering an effective amount of afatinib combined with at least one other anti-cancer agent for the treatment of EGFR-mutated cancer.
- Claim 10: A method utilizing afatinib in combination with a chemotherapeutic agent, such as cisplatin or pemetrexed, to treat NSCLC.
Dependent Claims
- Specify dosage ranges, administration sequences, or particular combinations.
- Detail the types of cancers (e.g., NSCLC, glioblastoma).
- Cover specific mutation types (e.g., exon 19 deletions, L858R mutations).
Claim Scope Highlights:
| Claim Type |
Key Focus |
Limitations |
| Independent |
Broad method of combining afatinib with other agents |
Specifies cancer types (mainly NSCLC), mutation profile |
| Dependent |
Specific dosages, combinations, or patient subsets |
Narrower scope, e.g., dosage ranges 20-50 mg/day |
Claim Language Extracts:
"A method of treating a subject having an EGFR mutation-positive cancer, comprising administering to the subject an effective amount of afatinib and at least one additional anti-cancer agent."
"The method of claim 1, wherein the additional anti-cancer agent is a platinum-based chemotherapeutic agent."
Patent Landscape and Prior Art
Major Patent Families & Competitors
| Patent Family |
Assignee |
Focus |
Key Similarities |
Notable Differences |
| WO 2009/050890 |
AstraZeneca |
EGFR inhibitors + chemotherapy |
Similar focus on combination therapy |
Different agents, broader scope |
| US 8,393,159 |
Pfizer |
EGFR kinase inhibitors |
Monotherapy focus |
No combination claims |
| US 7,939,248 |
Roche |
Targeted therapies for cancer |
Specific mutation targeting |
Different drug combinations |
Relevant Prior Art
- European Patent EP 2 147 219 (AstraZeneca, 2012): Involving combination of EGFR inhibitors with chemotherapeutic agents.
- US 7,879,663 (Pfizer, 2011): Monotherapy kinase inhibitor claims.
- US 8,024,235 (Roche, 2011): Combination of EGFR inhibitors with other targeted therapies.
Legal Status & Litigation
While there have been no publicly documented litigations specifically challenging 8,497,393, the patent landscape in EGFR-targeted therapy is litigious, notably involving products like afatinib (sold as Giotrif or Gilotrif). The patent’s granted status grants holder exclusivity until approximately 2030 assuming maintenance fees are paid.
Comparison with Similar Patents
| Aspect |
Patent 8,497,393 |
US 8,393,159 |
WO 2009/050890 |
US 8,024,235 |
| Focus |
Combination therapy with afatinib |
Monotherapy kinase inhibitors |
EGFR + Chemotherapy |
EGFR + targeted therapy |
| Cancer Types |
NSCLC primarily |
NSCLC, others |
Multiple cancers |
Various cancers |
| Claim Scope |
Specific combinations & dosing |
Broad kinase inhibitors |
Specific combinations |
EGFR inhibitors only |
Implication: Patent 8,497,393 narrows scope to specific kinase inhibitors (afatinib) plus other agents, potentially offering broader protection compared to more general patents.
Regulatory and Patent Policies
- Patent Term: Expiry usually 20 years from filing date (2010), subject to maintenance fees; expected expiration around 2030.
- Pediatric & Orphan Drug Exclusivity: No additional exclusivity granted under U.S. law for this patent.
- Use of Markush Groups: The claims encompass a broad class of compounds by including "at least one other anti-cancer agent," giving flexibility in subsequent patent applications for specific combinations.
Deep Dive into Key Claims and Their Strategic Importance
Claim 1: Broad Method for Combining Afatinib with Other Agents
- Strategic Value: Provides broad protection for all combination therapies involving afatinib with any other anti-cancer agent for EGFR-mutated cancers.
- Risk Factors: Potential for invalidation based on prior art disclosing similar combination therapies.
Claim 10: Specific Chemotherapy in NSCLC
- Strategic Value: Protects the use of afatinib with platinum-based chemotherapeutics, aligning with standard-of-care protocols.
- Market Impact: Impacts competitors developing alternative combinations.
Limitations and Flexibilities:
- Claims are constructed to prevent easy workarounds, but narrow subsequent dependent claims allow competitors to design around by choosing different agents or dosing schedules.
Conclusion
Patent 8,497,393 constitutes a significant element in the IP landscape governing combination therapies involving afatinib for EGFR mutation-positive cancers, especially NSCLC. Its broad independent claims and targeted claims position it as a foundational patent for subsequent innovations and commercialization strategies. Competitors must navigate its scope carefully, with particular attention paid to its claims involving specific combinations, dosages, and treatment methods.
Key Takeaways
- The patent protects combination methods involving afatinib, targeting EGFR-mutant cancers, predominantly NSCLC.
- It features broad independent claims that cover a wide range of combination therapies, supplemented by narrower dependent claims.
- The patent landscape in EGFR-targeted therapy is densely populated with similar patents; this patent’s scope gives it strategic importance.
- Ongoing patent filings and claims adjustments are likely to refine or challenge its scope.
- Its expiration predates 2030, but licensing, patent enforcement, and challenge risks remain pertinent.
FAQs
1. Does Patent 8,497,393 cover all uses of afatinib?
No. It specifically covers combination methods involving afatinib and other agents for treating EGFR-mutated cancers, not monotherapy or non-EGFR indications.
2. Can competitors develop other combination therapies that do not infringe?
Yes. They can avoid infringing by using different agents, alternative dosage regimens, or different target mutations outside its scope.
3. How does this patent influence drug development?
It provides a protected method for companies developing combination therapies involving afatinib, encouraging innovations within its scope but possibly limiting freedom to operate without licensing.
4. Are there any known litigations involving this patent?
Currently, no publicly available litigation is targeting this patent; however, patent disputes in EGFR inhibitors are common globally.
5. What is the typical lifespan of such patents?
With maintenance fees paid, it is expected to be valid until around 2030, after which generic versions could enter the market depending on licensing or patent challenges.
References
[1] USPTO, "Patent No. 8,497,393," issued July 23, 2013.
[2] WIPO, "International Patent Application," published 2010.
[3] Prior art references in patent citations, including WO 2009/050890, US 8,393,159, and others.
More… ↓
⤷ Start Trial
|
